Dosage unit comprising a prostaglandin analog for treating constipation
First Claim
Patent Images
1. A dosage unit for use in relieving or preventing constipation in a human patient comprising a prostaglandin (PG) analog represented by Formula (I) and/or its tautomers, and a pharmaceutically suitable excipient, wherein dosage unit contains said PG analog in the range of about 6-96 μ
- g;
7 Assignments
0 Petitions
Accused Products
Abstract
A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention comprises a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects.
-
Citations
19 Claims
- 1. A dosage unit for use in relieving or preventing constipation in a human patient comprising a prostaglandin (PG) analog represented by Formula (I) and/or its tautomers, and a pharmaceutically suitable excipient, wherein dosage unit contains said PG analog in the range of about 6-96 μ
-
10. A method for relieving or preventing constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) a PG analog represented by Formula (I) and/or its tautomers, in the range of about 6-96 μ
- g and (ii) a pharmaceutically suitable excipient.
- View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18, 19)
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeSucampo AG (Mallinckrodt plc)
-
Original AssigneeSucampo AG (Mallinckrodt plc)
-
InventorsPatchen, Myra L., Ueno, Ryuji
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current514/456
-
CPC Class CodesA61K 31/557 Eicosanoids, e.g. leukotrie...A61P 1/00 Drugs for disorders of the ...A61P 1/10 LaxativesA61P 1/14 Prodigestives, e.g. acids, ...A61P 43/00 Drugs for specific purposes...C07C 53/23 containing ringsC07D 311/94 condensed with rings other ...
